Allogene Therapeutics, Inc.
About Allogene Therapeutics, Inc.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $0
- Net income
- -$190.9M
- Total assets
- $415.9M
- Market cap
- $648.9M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $209.3M
- Operating income
- -$209.3M
- Income tax
- $0
- Net income
- -$190.9M
- EPS (basic)
- $-0.87
- EPS (diluted)
- $-0.87
Balance sheet
- Total assets
- $415.9M
- Current assets
- $257.7M
- Total liabilities
- $123.4M
- Current liabilities
- $32.5M
- Shareholders’ equity
- $292.5M
Cash flow
- Operating cash flow
- -$149.2M
- Investing cash flow
- $95.6M
- Financing cash flow
- $30.2M
- Net cash flow
- -$23.5M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $648.9M
- EPS (diluted)
- $-0.87
- Shares outstanding
- 350.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 11, 2018
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $190.9M in FY2025.
- Trading 40% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Allogene Therapeutics, Inc..
Write a review
News about Allogene Therapeutics, Inc.
News & sentiment via Polygon.io
